ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Investigating the Long-term Durability of Prosthetic Valves in Patients Who Have Undergone Tetralogy of Fallot Surgery with Transannular Patch.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesThis study aimed to determine the longevity of bioprosthetic valves (BPVs) or valved conduits in the pulmonary position and the factors associated with prosthetic valve longevity in patients who underwent surgical repair of tetralogy of Fallot (TOF).
methodsWe performed a single-centre retrospective study in patients undergoing placement of a bioprosthesis or valved conduit in patients operated for TOF with a transannular patch. The primary end-point was freedom from pulmonary valve replacement (PVR) reintervention. The composite secondary end-point was freedom from PVR reintervention and structural valve degeneration.
resultsA total of 211 patients undergoing 255 operations were identified. The median age at first PVR was 15.4 years (IQR 12.3-20.7 years). The freedom from reintervention at 5, 10, and 15 years was 94%, 77%, and 64%, respectively. Multivariable analysis shows that factors that are independently associated with a more significant hazard of reintervention are younger age, smaller valve size, and male sex. Of the implanted prosthetic valves, 122 were bioprosthesis; 38 (18%) were homografts; 37 (17%) percutaneous valve, and 14 (7%) were other prosthetic valves or conduits. The freedom from reintervention was not different between homografts and all other heterografts (P = 0.938). Percutaneous valves showed an average longevity of 9.4 years, significantly lower than other prosthetic valves (P = 0.007).
conclusionsYounger patient age and a smaller valve size were associated with reduced BPV durability. There is a concern about an early PVR to preserve right ventricle function overall during adolescent age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.